
iConsensus draws on the agility and specialist knowledge of SMEs and the know-how of academic experts to make biological drug development faster, cheaper and more efficient.
iConsensus draws on the agility and specialist knowledge of SMEs and the know-how of academic experts to make biological drug development faster, cheaper and more efficient.
As we mark the Innovative Health Initiative’s first birthday on 30 November, we look back on what we have achieved so far, and offer a glimpse of our plans for the coming year.
The IHI Governing Board has formally approved the Strategic Research and Innovation Agenda (SRIA), which will guide IHI’s scientific priorities in the years to come.
IHI is funded jointly by the EU and by industry associations representing Europe’s life science industries.
Our governance structure ensures that IHI benefits from the input of a diverse range of stakeholders.
EHDEN generates evidence for diseases and treatments using a network of nearly 100 data partners and over 400 million electronic health records
The Innovative Health Initiative (IHI) has launched its first calls for proposals, with topics on diseases such as cancer, cardiovascular disease and neurodegenerative diseases, as...